Fig. 6

Treatment with monoclonal antibody (mAb) against receptor activator of nuclear factor κB ligand (anti-RANKL) prevents erosive joint damage in delayed-type hypersensitivity arthritis (DTHA) but has no effect on new bone formation. Mice were treated with 500 μg of anti-RANKL mAb or isotype control in 200 μl of phosphate-buffered saline three times weekly from the time of immunization (day −7). a Histopathological scoring of inflammation, periarticular and subchondral pannus formation, cartilage damage, bone resorption, and bone formation on day 11 after arthritis induction in paws from DTHA mice treated with either anti-RANKL or isotype control (mean ± standard error of the mean, n = 10). ***p < 0.001 (Student’s t test). b Representative immunohistochemical osteocalcin staining of arthritis paws on day 11 after arthritis induction in anti-RANKL- and isotype control–treated mice (left panel original magnification × 40, right panel original magnification × 400). b bone, c cartilage, gt granulation tissue, i inflammation, nb new bone